Trial Profile
Use of TCC capacity assay to monitor complement inhibition in patients treated with eculizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Pharmacodynamics
- 21 Oct 2015 New trial record
- 18 Sep 2015 Results presented at Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.